

requirements of this AD can be accomplished.

(d) This amendment becomes effective on January 3, 1994.

Issued in Renton, Washington, on December 10, 1993.

Bill R. Boxwell,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 93-30651 Filed 12-15-93; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

15 CFR Part 943

[Docket No. 80851-1105]

RIN 0648-AB49

Flower Garden Banks National Marine Sanctuary Regulations

AGENCY: Office of Ocean and Coastal Resource Management (OCRM), National Ocean Service (NOS), National Oceanic and Atmospheric Administration (NOAA), Commerce (DOC).

ACTION: Notice of effective date.

SUMMARY: On November 20, 1991, the Under Secretary of Commerce for Oceans and Atmosphere transmitted the notice of designation for the Flower Garden Banks National Marine Sanctuary to Congress. The Sanctuary is two separate areas of ocean waters over and surrounding the East and West Flower Garden Banks, and the submerged lands thereunder including the Banks, in the northwestern Gulf of Mexico. The area designated at the East Bank is located approximately 120 nautical miles south-southwest of Cameron, Louisiana, and encompasses 19.20 square nautical miles. The area designated at the West Bank is located approximately 110 nautical miles southeast of Galveston, Texas, and encompasses 22.50 square nautical miles. The notice of designation and implementing rules were published on December 5, 1991 (56 FR 63634). They could not take effect until Congress had 45 days of continuous session to review the terms of designation, or until legislation providing for designation was signed into law.

On March 9, 1992, the President signed into law Public Law 102-251, which, among other matters, provides that the designation of the Flower Garden Banks National Marine Sanctuary took effect on January 17, 1992. Because Public Law 102-251 does not specifically provide an effective date

for the Sanctuary regulations, this document establishes the effective date of the regulations.

EFFECTIVE DATE: The final regulations in 15 CFR part 943 published on December 5, 1991 (56 FR 63634) shall take effect on January 18, 1994.

FOR FURTHER INFORMATION CONTACT: Edward Lindelof, Gulf and Caribbean Regional Manager, Sanctuaries and Reserves Division, Office of Ocean and Coastal Resource Management, National Ocean Service, National Oceanic and Atmospheric Administration, 1305 East West Highway, SSMC-4, Silver Spring, MD 20910 (301/713-3137).

Federal Domestic Assistance Catalog Number 11.429 Marine Sanctuary Program.

Dated: December 9, 1993.

W. Stanley Wilson,

Assistant Administrator for Ocean Services and Coastal Zone Management.

[FR Doc. 93-30599 Filed 12-15-93; 8:45 am]

BILLING CODE 3510-08-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Roxarsone Tablets and Liquid

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect codification of two previously approved new animal drug applications (NADA's) held by I. D. Russell Co., Laboratories. The NADA's provide for the use of roxarsone tablets and liquid in the drinking water of growing chickens and turkeys for improved rate of weight gain, improved feed efficiency, and improved pigmentation.

EFFECTIVE DATE: December 16, 1993.

FOR FURTHER INFORMATION CONTACT: Dianne T. McRae, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1623.

SUPPLEMENTARY INFORMATION: The I. D. Russell Co., Laboratories, 1301 Iowa Ave., Longmont, CO 80501, is sponsor of approved NADA's 6-019 and 6-081 for roxarsone tablets and liquid, respectively. The tablets and liquid are used to prepare medicated drinking water containing roxarsone at a concentration of 72 milligrams per gallon. Consumption of the medicated

drinking water by chickens and turkeys throughout their growing period results in improved rate of weight gain, improved feed efficiency, and improved pigmentation. NADA 6-019 (tablets) was originally approved on August 30, 1946, and NADA 6-081 (liquid) was originally approved on November 14, 1946. FDA is amending the regulations in § 520.2088 (21 CFR 520.2088) by adding new paragraph (c) and by adding new § 520.2089 to reflect these NADA's.

The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

In accordance with the freedom of information (FOI) provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(i) (21 CFR 514.11(e)(2)(i)) for NADA's approved prior to July 1, 1975, FOI summaries of safety and effectiveness data and information submitted to support approval of the applications are not required.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

2. Section 520.2088 is amended by adding new paragraph (c) to read as follows:

§ 520.2088 Roxarsone tablets.

* * * * *

(c)(1) *Specifications.* Each tablet contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic acid).

(2) *Sponsor.* See No. 017144 in § 510.600(c) of this chapter.

(3) *Related tolerances.* See § 556.60 of this chapter.

(4) *Conditions of use in growing chickens and growing turkeys—(i) Amount.* 1 tablet in each gallon of drinking water (0.002 percent roxarsone).

(ii) *Indications for use.* For improved rate of weight gain, improved feed efficiency, and improved pigmentation.

(iii) *Limitations.* Administer continuously throughout growing